Skip to main content
CRSP
NASDAQ Life Sciences

CRISPR Therapeutics Q2 2026: CASGEVY Revenue Surges to $76M, Cash Runway Extended Past 24 Months

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$50.7
Mkt Cap
$4.781B
52W Low
$44.12
52W High
$78.48
52W Position info
15% above low
Off High info
35% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

CRSP is trading near its 52-week low of $44.12 (15% above the low).

Summary

CRISPR Therapeutics posted Q2 2026 results highlighted by $76M in CASGEVY revenue, a narrower net loss, and a robust $2.36B cash position. In July, the FDA broadened CASGEVY's label to include patients ages 2 and older.


Key Events · Earnings and Guidance · CRSP

  • CASGEVY Revenue Hits $76M

    Driven by patient demand and label expansion, Q2 2026 CASGEVY revenue reached $76 million—a 151% increase year-over-year and 78% sequential growth.

  • Net Loss Narrows to $91.2M

    The net loss improved to $91.2 million from $208.5 million in Q2 2025, aided by $10 million in collaboration revenue and lower acquired IPR&D costs.

  • Cash Runway Extended Past 24 Months

    As of June 30, 2026, cash, cash equivalents, and marketable securities stood at $2.36 billion, following a $600 million convertible note offering completed in March 2026.

  • FDA Expands CASGEVY Label to Ages 2+

    In July 2026, the FDA approved CASGEVY for patients ages 2 years and older with sickle cell disease or transfusion-dependent beta thalassemia, significantly broadening the addressable market.


Analysis · CRSP · Life Sciences

A standout quarter for CRISPR Therapeutics saw CASGEVY revenue climb to $76 million, marking a 151% year-over-year leap and a 78% sequential gain. The balance sheet remains formidable at $2.36 billion in cash, reinforced by a $600 million convertible note offering in March, which pushes the cash runway beyond 24 months. The net loss contracted sharply to $91.2 million from $208.5 million a year ago, thanks to higher collaboration revenue and a drop in acquired IPR&D costs. Adding to the momentum, the FDA in July expanded CASGEVY's label to patients as young as 2 years old, unlocking a new patient segment. Meanwhile, the CFO and General Counsel adopted 10b5-1 trading plans—routine in nature but noteworthy given the stock's recent strength.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRSP was trading at $50.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $44.12 to $78.48. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRSP - Latest Insights

CRSP
Nov 10, 2026, 1:48 PM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $45.48
Real-time Price: $40.73 info
Change: -$4.75 (-10%) info
Market Cap: $3.916B info
CRSP
Nov 09, 2026, 9:16 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $50.42
Real-time Price: $40.73 info
Change: -$9.69 (-19%) info
Market Cap: $3.916B info
CRSP
Nov 02, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $49.98
Real-time Price: $40.73 info
Change: -$9.25 (-19%) info
Market Cap: $3.916B info
CRSP
Nov 02, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $49.01
Real-time Price: $40.73 info
Change: -$8.28 (-17%) info
Market Cap: $3.916B info
CRSP
Nov 02, 2026, 4:06 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $49.01
Real-time Price: $40.73 info
Change: -$8.28 (-17%) info
Market Cap: $3.916B info